BBNX BETA BIONICS

Beta Bionics to Host Investor Event on June 22, 2025

Beta Bionics to Host Investor Event on June 22, 2025

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central Time (8:00 am Eastern Time) and conclude at approximately 8:30 am Central Time (9:30 am Eastern Time).

Members of the Company’s management team, led by Sean Saint, President and CEO, will present at the event. The agenda will include updates on commercial and financial performance, a demonstration of the patch pump in development, a review of the adaptive closed-loop algorithm, and new real-world clinical data.

The Company invites investors to join the event via live webcast, a link to which will be available on the Company’s website in the “Investors—Events & Presentations” section at . Following the event, a replay of the webcast and its accompanying slide presentation will be archived on the Company’s website.

Investors who would like to attend the event in-person will be required to register, which can be done by contacting the Company’s investor relations representative at .

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit .

Investor Relations:

Blake Beber

Head of Investor Relations

Media and Public Relations:

Karen Hynes

Vice President of Marketing

Source: Beta Bionics, Inc.



EN
09/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BETA BIONICS

 PRESS RELEASE

Beta Bionics to Present at the TD Cowen 46th Annual Health Care Confer...

Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen’s 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time). A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at , and will be archived there for future repl...

 PRESS RELEASE

Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Res...

Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026 IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2025 and introduced its annual guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial Highlights & Key Metrics Net sales of $32.1 million, up 57% compared to $20.4 million in the fourth quarter of ...

 PRESS RELEASE

Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial R...

Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and...

 PRESS RELEASE

Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topl...

Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025. Members of the Company’s management team will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 finan...

 PRESS RELEASE

Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Res...

Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026 IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026. Topline financial results covered in the pre-release are expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy ben...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch